The effects of oxidation products of arachidonic acid and n3 fatty acids on vascular and platelet function

Free Radical Research

Volumn 45, Issue 4, 2011, Pages 469-476

  Barden, Anne ^a   Mas, Emilie ^a   Henry, Peter ^a   Durand, Thierry ^b   Galano, Jean Marie ^b   Roberts II, L Jackson ^c   Croft, Kevin D ^a   Mori, Trevor A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

isofurans; Isoprostanes; neuroprostanes; phytoprostanes; platelet aggregation; vascular reactivity

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; ISOPROSTANE DERIVATIVE; LINOLENIC ACID; OMEGA 3 FATTY ACID;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL FUNCTION; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; FATTY ACID OXIDATION; HUMAN; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADULT; AGED; ALPHA-LINOLENIC ACID; ANIMALS; AORTA; ARACHIDONIC ACID; BLOOD PLATELETS; CYCLOPENTANES; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; F2-ISOPROSTANES; FATTY ACIDS, UNSATURATED; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PLATELET AGGREGATION; RATS; RATS, WISTAR; YOUNG ADULT;

RATTUS;

EID: 79952381038     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2010.544730     Document Type: Article

References (33)

1. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000;28:1815-1826. (Pubitemid 30628668)
2. Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18:1791-1800. (Pubitemid 39602265)
3. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vas Biol 2005;25:279-286. (Pubitemid 40189146)
4. Thoma I, Krischke M, Loeffler C, Mueller MJ. The isopros-tanoid pathway in plants. Chem Phys Lipids 2004;128: 135-148.
5. Nourooz-Zadeh J, Halliwell B, Anggard EE. Formation of a novel class of F-3-isoprostanes during peroxidation of eicos-apentaenoic acid (EPA). Adv Prostaglandin Thromboxane Leukot Res 1997;433:185-188. (Pubitemid 28231810)
6. Roberts LJ, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998;273:13605-13612. (Pubitemid 28268404)
7. nd . Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci USA 2002; 99:16713-16718. (Pubitemid 36034038)
8. nd, Fessel J P. The biochemistry of the isopros-tane, neuroprostane, and isofuran pathways of lipid peroxida-tion. Chem Phys Lipids 2004;128:173-186. (Pubitemid 38167386)
9. Cracowski JL, Devillier P, Durand T, Stanke-Labesque F, Bessard G. Isoprostanes: an emerging role in vascular physiology and disease? Chem Phys Lipids 2004;128:75-83.
10. Cracowski JL, Devillier P, Durand T, et al. Vascular biology of the Isoprostanes. J Vasc Res 2001;38:93-103. (Pubitemid 32337211)
11. Hou X, Roberts LJ, Gobeil F, Taber DF, Kanai K, Abran D, Brault S, Checchin D, Sennlaub F, Lachapelle P, Varma DR, Chemtob S. Isomer-specific contractile effects of a series of synthetic F-2-isoprostanes on retinal and cerebral microvas-culature. Free Radic Biol Med 2004;36:163-172. (Pubitemid 38117234)
12. Marliere S, Cracowski JL, Durand T, Chavanon O, Bessard J, Guy A, Stanke-Labesque F, Rossi JC, Bessard G. The 5-series F2-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein. Br J Pharmacol 2002;135: 1276-1280. (Pubitemid 34259130)
13. Cranshaw JH, Evans TW, Mitchell JA. Characterization of the effects of isoprostanes on platelet aggregation in human whole blood. Br J Pharmacol 2001;132:1699-1706. (Pubitemid 32397961)
14. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997;17:2309-2315. (Pubitemid 28015962)
15. El Fangour S, Guy A, Vidal J-P, Rossi J-C, Durand T. Total synthesis of phytoprostane F1 and its 16 epimer. Tetrahedron Lett 2003;44:2105-2108. (Pubitemid 36197762)
16. 1 Types I and II. J Org Chem 2004;69:2498-2503. (Pubitemid 38419065)
17. 4t -Isoprostane methyl ester. Tetrahedron Lett 2000; 41:3859-3862. (Pubitemid 30340078)
18. Taber DF, Fessel JP, Roberts LJ, II. A nomenclature system for isofurans. Prostaglandins Other Lipid Mediat 2004;73:47-50. (Pubitemid 38446470)
19. Taber DF, Zhang Z. Synthesis of the enediol isofurans, endogenous oxidation products of arachidonic acid. J Org Chem 2006;71:926-933. (Pubitemid 43209234)
20. Morrow JD, Minton TA, Roberts LJ. The F2-isoprostane, 8-epi-prostaglandin-F2-alpha, a potent agonist of the vascular thromboxane endoperoxide receptor, is a platelet thrombox-ane endoperoxide receptor antagonist. Prostaglandins 1992; 44:155-163.
21. Barden AE, Croft KD, Durand T, Guy A, Mueller MJ, Mori TA. A randomized controlled trial of the effect of flaxseed oil supplementation on F1-phytoprostanes in men. J Nutr 2009; 139:1890-1895.
22. 2 receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets. Biochem Pharmacol 2008;75:2301-2315.
23. Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Throm Vasc Biol 1997;17:279-286. (Pubitemid 27098185)
24. Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrilolytic and vascular function in Type 2 diabetic patients. Atherosclerosis 2003; 166:85-93. (Pubitemid 35449604)
25. Mori TA, Woodman RJ. The independent effects of eicosap-entaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006;9:95-104. (Pubitemid 44090031)
26. 2 -isoprostane excretion in non insulin dependent diabetic patients. Metabolism 1999; 48:1402-1408. (Pubitemid 29536439)
27. Mas E, Woodman RJ, Burke V, Puddey IB, Beilin LJ, Durand T, Mori TA. The omega-3 fatty acids EPA and DHA decrease plasma F2-isoprostanes: results from two placebo controlled interventions. Free Rad Res 2010;44: 983-990.
28. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003;35:772-781. (Pubitemid 37329480)
29. Barden AE, Mori TA, Dunstan JA, Taylor AL, Thornton CA, Croft KD, Beilin LJ, Prescott SL . Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. Free Rad Res 2004;38:233-239. (Pubitemid 38247991)
30. Gao L, Yin L, H Milne GL, Porter NA, Morrow JD. Formation of F-ring isoprostane like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem 2006; 281:14092-14099. (Pubitemid 43848336)
31. Yin H, Liu W, Goleniewska K, Porter NA, Morrow JD, Peebles RS, Jr. Dietary supplementation of omega 3 fatty acid containing fish oil suppresses F(2) - isoprostanes but enhances inflammatory cytokine response in a mouse model of ovalbumin-induced allergic lung inflammation. Free Radic Biol Med 2009;47:622-628.
32. Barden AE, Croft KD, Durand T, Guy A, Mueller MJ, Mori TA. A randomized controlled trial of the effect of flaxseed oil supplementation on F1-phytoprostanes in men. J Nutr 2009;139:1890-1895.
33. Cheung PY, Stevens JP, Haase E, Stang L, Bigam DL, Etches W, Radomski MK. Platelet dysfunction in asphixiated newborn piglets resuscitated with 21% and 100% oxygen. Pediatr Res 2006;59:636-640. (Pubitemid 43740002)